Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention is directed to ⁇ -lactamase inhibitors useful in combination with ⁇ -lactam antibiotics. More specifically, the present invention is directed to novel 3,6-disubstituted penam sulfone derivatives which demonstrate potent ⁇ -lactamase inhibitory activity.
• Penicillins and cephalosporins are the most frequently and widely used ⁇ -lactam antibiotics. However, the development of bacterial resistance to these antibiotics has had a damaging effect on maintaining the effective treatment of bacterial infections.
• U.S. Patent No. 4,234,579 discloses penicillanic acid 1,1 -dioxide (i.e., Sulbactam) useful for enhancing the activity of a number of ⁇ -lactam antibiotics.
• U.S. Patent No. 4,562,073 discloses a penicillin derivative (Tazobactam) useful as a ⁇ -lactamase inhibitor.
• U.S. Patent Nos. 4,287,181 and 5,637,579 disclose penicillanic acid derivatives useful in enhancing the effectiveness of ⁇ -lactam antibiotics.
• the present invention provides compounds having ⁇ -lactamase inhibitory activity against both Class A and Class C serine ⁇ -lactamases, which compounds have the formula (A):
• X is CH or NH;
• R j is cyano, methoxy or acetamido;
• R j is hydrogen, alkyl, a negative charge, a cation selected from the group consisting of sodium, potassium and tetraalkylammonium and acyloxyalkyl, or alkoxycarbonyloxyalkyl;
• R. is hydrogen, acyl, trisubstituted silyl, carbamoyl, di-(C M alkyl)aminocarbonyl or an amino acid residue; or pharmaceutically acceptable salts thereof.
• Heterocyclic rings for R can be aromatic or non-aromatic and have one to three heteroatoms, the same or different, selected from oxygen, nitrogen and sulfur. Examples include 1,2,3-triazole, isoxazole, imidazole or yridine.
• R when disubstituted amino are di-(C ⁇ - 4 alkyl)amino where the alkyl groups are the same or different.
• R when an ester are alkyl esters where the alkyl group has 1 to 4 carbon atoms.
• R 2 when trisubstituted silyl are tri-(C ⁇ - 4 alkyl)silyl where the alkyl groups are the same or different.
• R 2 when acyl are (C ⁇ . 4 alkyl)carbonyl.
• amino acid residues for R 2 are glycyl, alanyl, leucyl, isoleucyl and valyl.
• the compounds of the present invention are those of the formula set forth above where n is 1 and R is 1,2,3-triazole, isoxazole, imidazole or pyridine; R : is sodium; and R j is hydrogen; or pharmaceutically acceptable salts thereof.
• the asymmetric centres have the 2S, 3S, 5R, 6R configuration.
• the compounds of the present invention are: (2S, 3S, 5R, 6R)-6-Hydroxymethyl-3-methyl-4,4,7-trioxo-3-[l,2,3]triazol-l-ylmethyl- 4-lambda(6)-thia-l-aza-bicyclo[3.2.0)]heptane-2-carboxylic acid; (2S, 3R, 5R, 6R)-6-Hydroxymethyl-3-(methoxyimino-methyl)-3-methyl-4,4,7-trioxo- 4-lambda(6)-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2S, 3S, 5R, 6R)-6-Hydroxymethyl-3-methyl-3-(3-nitrilo-propenyl)-4,4,7-trioxo- 4-lambda(6)-thia-l-azabicyclo[3.2.0]heptane
• alkyl and “alkoxy” are used to represent straight or branched carbon chains of 1-6 atoms.
• halogen is used to represent chlorine, bromine, fluorine and iodine.
• the compounds of this invention contain asymmetric carbon atoms and thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. It is recognized that one optical isomer, including diastereomer and enantiomer, or stereoisomer may have favorable properties over the other. Thus when disclosing and claiming the invention, when one racemic mixture is disclosed, it is clearly contemplated that both optical isomers, including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well.
• the compounds of the present invention may also be used in the form of a pharmaceutically acceptable acid addition salt having the utility of the free base.
• Such salts prepared by methods well known in the art, may be formed with both inorganic or organic acids, e.g., fumaric, benzoic, maleic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanolsulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, annamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene- sulfonic, hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric, and nitric acids.
• inorganic or organic acids e.g., fuma
• This invention also provides a process for preparing compounds of formula A which comprise one of the following: a) deprotecting a compound of formula III:
• Removal of protecting groups, as illustrated by process a) can be carried out by processes known in the art to provide the compound of formula A.
• a racemic mixture may be converted to a mixture of optically active diastereoisomers by reaction with a single enantiomer of a 'resolving agent' (for example by diastereomeric salt formation or formation of a covalent bond).
• the resulting mixture of optically active diastereoisomers may be separated by standard techniques (e.g crystallisation or chromatography) and individual optically active diastereoisomers then treated to remove the 'resolving agent' thereby releasing the single enantiomer of the compound of the invention.
• Chiral chromatography using a chiral support, eluent or ion pairing agent
• the compounds of formula A may be isolated in the form of a salt of a pharmaceutically acceptable acid, e.g. an organic or inorganic acid by treatment with an acid such as described above.”
• the compounds of the present invention may be prepared by any suitable method which will be recognized by those skilled in the art. However, the present compounds may be advantageously prepared according to the Schemes set forth below.
• the monomeric formaldehyde/THF solution was prepared as follows: Paraformaldehyde (30 g. 1.0 mol) and ⁇ -toluenesulfonic anhydride (4.9 g, 15 mmol) were placed in a three-necked flask, and tetrahydrofuran (1.0 L) was added thereto. The mixture was heated and a slow distillation of the solvent was maintained.
• Representative compounds according to the present invention were tested in a microbiological assay in combination with the penicillin antibiotic piperacillin.
• the enhanced combined synergestic antibacterial activity is representative of the ⁇ - lactamase inhibitory properties of the compounds of the present invention.
• minimum inhibitory properties MIC's are determined in broth using several two-fold dilutions with a 1:1 ratio of piperacillin to inhibitor (N. A. Kuck, N. V. Jacobus, P. J. Peterson, W. J. Weiss, and R. T. Testa, Antibiotic Agents and Chemotherapy. 33:1964-1969 (1989)). The results are set forth in Table 1.
• Representative compounds of the present invention were also tested against a comercally available inhibitor, tazobactam, to determine inhibition of the AmpC and
• TEM-1 ⁇ -lactamase enzymes IC 50 values were determined spectrophotometrically using a 10 minute preincubation of enzyme with inhibitor at 25°C before addition of nitrocefin as a substrate. The results are also set forth in Table 1.
• the present compounds When the present compounds are employed for the above utility, they may be combined with one or more pharmaceutically acceptable carriers, e.g., solvents, dilutents, etc., and may be administered parentally in the form of sterile injectable solutions or suspensions containing from about 0.05% to about 5% suspending agent in an isotonic medium.
• Such pharmaceutical preparations may contain from about 0.05% to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and about 60% by weight.
• the effective dosage of active ingredient employed may vary depending upon the particular compound used, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 2 to 100 mg/kg of animal body weight, preferably given in divided doses two to four times a day. In general, the total daily dose is from about 100 mg to about 750 mg, preferably from about 100 to about 500 kg. Dosage forms suitable for internal use include from about 100 to 750 mg of active compound in intimate admixture with a liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the therapeutic situation.
• Liquid carriers include sterile water, polyethylene glycols, non-ionic-surfactants and edible oils such as corn, peanut, and sesame oils as appropriate.
• Adjuvants normally employed in the preparation of pharmaceutical preparations may be used, such as vitamin E, ascorbic acid, BHT and BHA.
• the present compounds may be administered parentally or intraperitoneally.
• Solutions or suspension of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
• Dispersions can be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical forms suitable for injection use include sterile aqueous solutions and sterile powders for the preparation of sterile injectable solutions or dispensors. In all cases, the forms must be sterile and must be fluid so that easy syringability exists. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms.
• the carrier may be a solvent or dispension medium containing, e.g., water, ethanol, apolyl (e.g., glyceol, propylene glycol and liquid polyethylene glycol) and vegetable oils.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cephalosporin Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22894903

Family Applications (1)

Country Status (20)

Families Citing this family (2)

Family Cites Families (6)

• 2000
  • 2000-01-26 EP EP00904498A patent/EP1144418A1/de not_active Withdrawn
  • 2000-01-26 IL IL14411600A patent/IL144116A0/xx unknown
  • 2000-01-26 TR TR2001/02133T patent/TR200102133T2/xx unknown
  • 2000-01-26 ID IDW00200101522A patent/ID29400A/id unknown
  • 2000-01-26 JP JP2000594815A patent/JP2002535335A/ja active Pending
  • 2000-01-26 KR KR1020017009276A patent/KR20010101649A/ko not_active Application Discontinuation
  • 2000-01-26 EA EA200100813A patent/EA200100813A1/ru unknown
  • 2000-01-26 CA CA002355738A patent/CA2355738A1/en not_active Abandoned
  • 2000-01-26 CZ CZ20012691A patent/CZ20012691A3/cs unknown
  • 2000-01-26 PL PL00349874A patent/PL349874A1/xx not_active Application Discontinuation
  • 2000-01-26 BR BR0007729-1A patent/BR0007729A/pt not_active IP Right Cessation
  • 2000-01-26 SK SK1014-2001A patent/SK10142001A3/sk unknown
  • 2000-01-26 WO PCT/US2000/001630 patent/WO2000043399A1/en not_active Application Discontinuation
  • 2000-01-26 AU AU26246/00A patent/AU2624600A/en not_active Abandoned
  • 2000-01-26 HU HU0200013A patent/HUP0200013A3/hu unknown
  • 2000-01-26 CN CNB008030766A patent/CN1188417C/zh not_active Expired - Fee Related
• 2001
  • 2001-05-25 ZA ZA200104323A patent/ZA200104323B/en unknown
  • 2001-07-24 NO NO20013640A patent/NO20013640D0/no not_active Application Discontinuation
  • 2001-07-26 BG BG105737A patent/BG105737A/xx unknown
• 2002
  • 2002-01-10 HK HK02100179.1A patent/HK1038747A1/zh unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events